"It is surprising to us that (infection) cases have extended beyond ReNu MoistureLoc into ReNu MultiPlus, that cases are now being reported in Europe (which are manufactured out of Milan, not Greenville) and that the company still cannot find a cause," she wrote on Thursday. Thus, "our single-point price target is lowered to $44 from $65. ... (And) risks to our price target include the lack of SEC filings, the unknown impact on the contact lens solution franchise, collateral damage to other franchises and permanent damage to the Bausch & Lomb name."